The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
- Resource Type
- Article
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia May 2022 22(5):e335-e339 - Subject
- Language
- ISSN
- 2152-2650